Researchers theorized on whether mass spectrometry-based analysis of the presented HLA ligands of cancer cell lines can be used to identify a tumor-associated HLA ligand.
Researchers sought to determine the optimal benefit/risk profile for ponatinib in patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Researchers sought to determine whether pevonedistat plus azacitidine would have efficacy in patients with higher-risk MDS compared with azacitidine alone.
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.
Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Researchers sought to determine whether therapy with azacitidine and venetoclax would be effective in patients with ASXL-1 somatic mutation higher-risk MDS.
